"Suven Pharmaceuticals a leading contract development and manufacturing organization (CDMO), announced that the National Company Law Tribunal (NCLT), vide its order pronounced on March 27, 2025 has sanctioned the Scheme of Amalgamation between Cohance Lifesciences Limited and Suven Pharmaceuticals Limited.
As per the terms of the Scheme, the merger will become effective from the opening business hours of the first day of the month immediately following the month in which all conditions specified under the Scheme are fulfilled, including receipt of approval from the Department of Pharmaceuticals, where applicable. The effective date will be duly intimated to the Stock Exchanges for public disclosure in accordance with applicable regulations. As previously communicated, the company expects to complete the amalgamation process by Q1FY26.
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals—antibody drug conjugates (ADCs), oligonucleotides, and small molecules. The combined entity will operate as an integrated, end-to-end partner to global innovator pharmaceutical companies, further supported by strong capabilities in the Specialty CDMO and API+ business segments. The merged platform is expected to enhance scale, broaden customer offerings, and drive operational synergies that will fuel long-term growth.
Vivek Sharma, executive chairman of Suven Pharmaceuticals, said, “The NCLT approval marks a milestone moment for both the companies, as we embark on a transformative phase. This merger enhances our global capabilities, particularly in the growing and highly specialized areas of ADCs. With Cohance's unique technological platform in ADC, we are well-positioned to become a $1 billion revenue company in next five years with higher CDMO contribution.”
Dr V Prasada Raju, managing director, Suven Pharmaceuticals, said, “The approval of the merger marks a significant milestone in our journey to build a differentiated and innovation-led CDMO platform from India. The combined capabilities of Suven and Cohance position us strongly in high-growth areas such as antibody drug conjugates (ADCs), oligonucleotides, and complex small molecules. These segments represent the future of pharmaceutical innovation, and our integrated approach—spanning development to commercial manufacturing—aims to deliver high-impact solutions to global innovator clients. We are also excited about the broader synergies this merger will unlock across our specialty CDMO and API+ business segments, enabling us to drive long-term value creation.”